Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Maher

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
International Journal of Toxicology|March 5, 2022
Polysorbate 80-Induced Anaphylactoid Reaction and the Effects on Cardiovascular Function: Dose Threshold and Species ComparisonMylène Pouliot, Jeanine Bussiere, Aldo Coppi, et al.
Toxicologic Pathology|March 4, 2020
Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and DogsPaula Katavolos, Gary Cain, Cindy Farman, et al.
Lab on a Chip|January 20, 2021
Cardiovascular microphysiological systems (CVMPS) for safety studies - a pharma perspectiveAmy Pointon, Jonathan Maher, Myrtle Davis, et al.
Toxicology and Applied Pharmacology|November 18, 2017
Individual serum bile acid profiling in rats aids in human risk assessment of drug-induced liver injury due to BSEP inhibitionSteven Cepa, David Potter, Lisa Wong, et al.
Toxicology and Applied Pharmacology|July 15, 2023
Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout ratsJonathan Maher, Nicola Stagg, Gary Cain, et al.
Journal of Leukocyte Biology|January 28, 2020
RIP1 kinase activity is critical for skin inflammation but not for viral propagationJoshua D Webster, Youngsu C Kwon, Summer Park, et al.
Clinical Pharmacology and Therapeutics|August 24, 2018
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium PerspectiveJ Gerry Kenna, Kunal S Taskar, Christina Battista, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo ActivityNaomi S Rajapaksa, Alberto Gobbi, Joy Drobnick, et al.
Journal of Medicinal Chemistry|May 15, 2019
Development of Potent and Selective Pyrazolopyrimidine IRAK4 InhibitorsMarian C Bryan, Joy Drobnick, Alberto Gobbi, et al.
Journal of Medicinal Chemistry|October 30, 2025
Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory DiseasesSnahel Patel, Huifen Chen, Eugene Varfolomeev, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
International Journal of Toxicology|March 5, 2022
Polysorbate 80-Induced Anaphylactoid Reaction and the Effects on Cardiovascular Function: Dose Threshold and Species ComparisonMylène Pouliot, Jeanine Bussiere, Aldo Coppi, et al.
Toxicologic Pathology|March 4, 2020
Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and DogsPaula Katavolos, Gary Cain, Cindy Farman, et al.
Lab on a Chip|January 20, 2021
Cardiovascular microphysiological systems (CVMPS) for safety studies - a pharma perspectiveAmy Pointon, Jonathan Maher, Myrtle Davis, et al.
Toxicology and Applied Pharmacology|November 18, 2017
Individual serum bile acid profiling in rats aids in human risk assessment of drug-induced liver injury due to BSEP inhibitionSteven Cepa, David Potter, Lisa Wong, et al.
Toxicology and Applied Pharmacology|July 15, 2023
Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout ratsJonathan Maher, Nicola Stagg, Gary Cain, et al.
Journal of Leukocyte Biology|January 28, 2020
RIP1 kinase activity is critical for skin inflammation but not for viral propagationJoshua D Webster, Youngsu C Kwon, Summer Park, et al.
Clinical Pharmacology and Therapeutics|August 24, 2018
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium PerspectiveJ Gerry Kenna, Kunal S Taskar, Christina Battista, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo ActivityNaomi S Rajapaksa, Alberto Gobbi, Joy Drobnick, et al.
Journal of Medicinal Chemistry|May 15, 2019
Development of Potent and Selective Pyrazolopyrimidine IRAK4 InhibitorsMarian C Bryan, Joy Drobnick, Alberto Gobbi, et al.
Journal of Medicinal Chemistry|October 30, 2025
Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory DiseasesSnahel Patel, Huifen Chen, Eugene Varfolomeev, et al.
Pageof 3